Immunotherapy News and Research

Latest Immunotherapy News and Research

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

FIT Biotech, a privately held biotechnology company developing novel, proprietary immunotherapies for HIV/AIDS and other viral diseases, announced results today from a Phase II clinical trial. The company's immunomodulator FIT-06 showed unprecedented long-term reductions in viral load (approximately 0.5 log) and statistically significant CD4 cell count increases in HIV-infected, previously untreated patients. The effect lasted longer than two years in the absence of any anti-retroviral therapy.

19 Jul 2010

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

This week, nearly 4,000 scientists from around the world gathered to report and discuss the latest advances in research on treatments, risk factors, and diagnosis for the health epidemic of the 21st century – Alzheimer's disease – at the Alzheimer's Association's 2010 International Conference on Alzheimer's Disease in Honolulu.

15 Jul 2010

Aduro BioTech announces issuance of two important patents

Aduro BioTech, a clinical-stage immunotherapy company, announced today the issuance of two important patents, the formation of a distinguished scientific advisory board, the addition of key members to its Board of Directors, and the reporting of preliminary top line long-term survival data from a Phase 1 clinical trial with 2 year follow-up.

15 Jul 2010

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company's Chairman and Chief Executive Officer, recently has received.

14 Jul 2010

AD may lead to increased risk of comorbid conditions, research shows

Pfizer Inc., together with its collaborator on the Alzheimer's Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 from two podium and four poster presentations.

14 Jul 2010

New research studies presented at Alzheimer's Association International Conference

The primary therapeutic target in Alzheimer's disease has been the beta amyloid peptide, which clusters outside cells in the brain to form sticky clumps known as plaques. Recently, more attention has been given to the tau protein, which aggregates inside the brain cells of people with Alzheimer's, forming neurofibrillary tangles. Precisely how these proteins interact in causing the disease is unclear.

14 Jul 2010

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

Having Alzheimer's disease may increase the risk of getting other potentially disabling health conditions, including seizures and anemia, according to new research presented today at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu, HI.

14 Jul 2010

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

12 Jul 2010

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week's 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field.

12 Jul 2010

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and Immunotope Inc, a biotechnology company focused on the development of immunotherapy products, today announced the formation of a joint venture Syntara LLC, to develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.

12 Jul 2010

New method enhances delivery of DNA payloads into cells

Chang Lu and his chemical engineering research group at Virginia Tech have discovered how to "greatly enhance" the delivery of DNA payloads into cells. The description of their work will be featured on the cover of Lab on a Chip (issue 16), the premier journal for researchers in microfluidics.

9 Jul 2010

Northwest Biotherapeutics raises $2.65M during second-quarter

Northwest Biotherapeutics, Inc., developer of the DCVax® personalized cancer vaccines, announced today that during the second quarter it raised funding of $2.65 million from investors. The funding included $1.75 million in purchases of restricted common stock of the Company by a number of private investors, together with purchases of restricted Common Stock totaling $900,000 by SDS Capital and by Ms. Linda F. Powers, Chair of the Company's Board.

7 Jul 2010

Epeius Biotechnologies receives notice of allowance from USPTO for gene delivery platform

Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances covering tumor-targeted gene delivery and precision-targeted cancer immunotherapy, respectively.

7 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

DBV Technologies (DBV), a biotech company specializing in food allergy with innovative products for diagnosis and treatment, announced today the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application. DBV Technologies will begin clinical investigation of its lead food allergy desensitization candidate, VIASKIN® PEANUT, for the desensitization to peanut allergy. The Company expects to commence recruitment of peanut allergy patients at several medical centers in the U.S. this month.

7 Jul 2010

Rogue stem cells capable of kick-starting melanoma skin cancer development discovered

Researchers at Stanford University School of Medicine in the US have discovered that rogue stem cells appear to be capable of kick-starting the development of melanoma skin cancer in humans.

3 Jul 2010

Gene diagnosis to be featured at 9th INT'L BIO FORUM & BIO EXPO JAPAN

9th INT'L BIO FORUM & BIO EXPO JAPAN, organized by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. "Gene diagnosis" is one of the featured topics for this year.

30 Jun 2010

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

CEL-SCI Corporation and researchers at the Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM) jointly announced today that a LEAPS-based vaccine (Ligand Epitope Antigen Presentation System) study has demonstrated the technology's potential using dendritic cells to stimulate the immune system to fight viral illnesses and other diseases.

29 Jun 2010

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

Scancell Holdings Plc,, the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

29 Jun 2010

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

AFREZZA (insulin human [rDNA origin]) Inhalation Powder, a well-tolerated, investigational ultra rapid acting mealtime insulin, as part of a diabetes treatment regimen, provides long-term glucose control comparable to usual insulin therapy but with a significantly reduced incidence of hypoglycemia and less weight gain in patients with Type 2 diabetes, according to a two-year study presented today at the American Diabetes Association's 70th Scientific Sessions.

29 Jun 2010

Immunotherapy News and Research

Latest Immunotherapy News and Research

FIT Biotech to present results of FIT-06 Phase II clinical trial at XVIII International AIDS 2010 Conference

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

Aduro BioTech announces issuance of two important patents

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

AD may lead to increased risk of comorbid conditions, research shows

New research studies presented at Alzheimer's Association International Conference

New research shows Alzheimer's disease may increase risk of other potentially disabling health conditions

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

New method enhances delivery of DNA payloads into cells

Northwest Biotherapeutics raises $2.65M during second-quarter

Epeius Biotechnologies receives notice of allowance from USPTO for gene delivery platform

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

FDA accepts DBV Technologies' IND for clinical study of VIASKIN for desensitization to peanut allergy

Rogue stem cells capable of kick-starting melanoma skin cancer development discovered

Gene diagnosis to be featured at 9th INT'L BIO FORUM & BIO EXPO JAPAN

LEAPS vaccine technology generates dendritic cells to stimulate immune system to fight viral illnesses

Scancell, immatics collaborate to develop ImmunoBody vaccines for colorectal cancer

AFREZZA provides long-term glucose control in Type 2 diabetics: Study

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Immunotherapy News and Research

Latest Immunotherapy News and Research

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Extending the reach of Amperia™

Newsletters you may be interested in